US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
SDEV
$7.48
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
SDEV
$7.48
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Novo Nordisk A/S Common Stock
(NY:
NVO
)
37.32
UNCHANGED
Delayed Quote
Updated: 7:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S Common Stock
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
99
100
Next >
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm
September 19, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
September 19, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
September 19, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial
↗
September 17, 2025
Via
Stocktwits
US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’
↗
September 16, 2025
Via
Stocktwits
Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study
↗
September 16, 2025
Via
Stocktwits
The Weight-Loss Craze Boosted The $186 Billion Telehealth Industry. What It Means For Investors.
↗
September 19, 2025
Telehealth companies are getting a fresh infusion of business thanks to obesity drugs. Find out which stocks are benefiting.
Via
Investor's Business Daily
Why Shares in Novo Nordisk Soared This Week
↗
September 19, 2025
Positive results from the trial further indicate that the company is poised to win the next battle in the weight loss drug market.
Via
The Motley Fool
Why Novo Nordisk Stock Popped Again Today
↗
September 18, 2025
A Wegovy pill may be the right medicine to get Novo Nordisk stock moving again.
Via
The Motley Fool
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
↗
September 18, 2025
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
Via
Benzinga
Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today
↗
September 18, 2025
Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.
Via
The Motley Fool
Topics
Government
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
↗
September 18, 2025
The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.
Via
Benzinga
Topics
ETFs
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
↗
September 18, 2025
Novo Nordisk A/S (NYSE:NVO) is showing promising signs of recovery with weight-loss pills, heart-healthy benefits, and bullish analyst reports, following a similar path to UnitedHealth Group Inc's...
Via
Benzinga
Topics
Artificial Intelligence
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
September 18, 2025
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
September 18, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
September 18, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy
↗
September 18, 2025
Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight.
Via
Investor's Business Daily
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
↗
September 18, 2025
Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease.
Via
Benzinga
Why Is Everyone Talking About Novo Nordisk Stock?
↗
September 18, 2025
Competition in various directions is affecting the company's fastest-growing product.
Via
The Motley Fool
'Offices Need To Start Feeling A Little Bit More Like Hotels,' Behind One CBRE Exec's Approach To The Future Of In-Person Work
↗
September 18, 2025
Via
Benzinga
Dow Futures Surge After Fed Signals Possibility Of More Rate Cuts This Year: META, PLTR, PYPL, GOOGL Among Stocks To Watch
↗
September 18, 2025
Via
Stocktwits
Topics
Economy
Stocks
Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up
↗
September 17, 2025
The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity.
Via
Stocktwits
Why Novo Nordisk Stock Popped Today
↗
September 17, 2025
Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now?
Via
The Motley Fool
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
September 17, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Class Action Filed Against Novo Nordisk A/S (NVO) Seeking Recovery for Investors - Contact Levi & Korsinsky
September 17, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
2 High-Yield Dividend Stocks You'll Wish You Had Bought 10 Years From Now
↗
September 17, 2025
These dividend payers cranked up their payouts over the past decade, and they could do it again.
Via
The Motley Fool
Why Novo Nordisk Stock Popped Today
↗
September 16, 2025
The Wegovy maker reported positive results from a clinical trial of a next-generation obesity treatment.
Via
The Motley Fool
Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition
September 16, 2025
Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable...
Via
MarketMinute
Topics
Earnings
Economy
Intellectual Property
Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy
↗
September 16, 2025
FDA warns Hims & Hers that its semaglutide products are misbranded due to misleading claims and asks for corrective steps within 15 days.
Via
Benzinga
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?
↗
September 16, 2025
Novo Nordisk has been in a downtrend for more than a year. But a reversal may be underway, and a rally may follow.
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
99
100
Next >
